Clinical trial enrollment is imperative to answer outstanding questions regarding safety, tolerability, and efficacy of alternative therapies29 including JAK2 and telomerase inhibitors, both of which have demonstrated promising early results in the treatment of ET. This evidence concerns the gene JAK2 and essential thrombocythemia.